DSP-2230 (ulotaront)
Schizophrenia
Key Facts
About Sumitomo Pharma
Sumitomo Pharma is a research-driven pharmaceutical company with a mission to deliver innovative therapeutic solutions for serious unmet medical needs. Its strategic direction is built on a foundation of internal R&D and strategic acquisitions, such as the merger with Myovant Sciences and the acquisition of Tolero Pharmaceuticals, to bolster its pipeline in key therapeutic areas. The company faces challenges from patent expirations but is actively investing in next-generation modalities like cell and gene therapies to drive future growth.
View full company profileTherapeutic Areas
Other Schizophrenia Drugs
| Drug | Company | Phase |
|---|---|---|
| Luvadaxistat (NBI-1065845) | Neurocrine Biosciences | Phase 2 |
| Cariprazine (Vraylar/Reagila) | Richter Gedeon | Approved |
| Lu AG13909 (PDE10A Inhibitor) | Lundbeck | Phase 1 |
| LATUDA (lurasidone HCl) | Sumitomo Pharma | Approved/Commercial |
| REXULTI (brexpiprazole) | Sumitomo Pharma | Approved/Commercial |
| RBP-7000 (risperidone depot) | Indivior PLC | Approved |
| COBENFY® (xanomeline/trospium) | Zai Lab | Approved |
| Undisclosed CNS Candidate | Alto Neuroscience | Phase 1 |
| HTL'149 | Nxera Pharma | Phase 1 |
| GPR52 Agonist | Nxera Pharma | Preclinical |
| Fanapt® (iloperidone) | Vanda Pharmaceuticals | Approved |
| Fanapt® (iloperidone) one month injectable | Vanda Pharmaceuticals | In Development |